Fennec Pharmaceuticals (FENC) Cash & Equivalents (2010 - 2025)

Fennec Pharmaceuticals (FENC) has 16 years of Cash & Equivalents data on file, last reported at $36.8 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 38.12% year-over-year to $36.8 million; the trailing twelve-month figure through Dec 2025 stood at $36.8 million (up 38.12% YoY), and the FY2025 full-year result was $36.8 million, up 38.12% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $36.8 million, up from $21.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $51.2 million in Q1 2024 and bottomed at $12.4 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $23.2 million (2022), against an average of $25.1 million.
• The widest annual swing landed in 2023, when Cash & Equivalents tumbled 58.33%; it then soared 285.74% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $21.1 million in 2021, then climbed by 12.67% to $23.8 million in 2022, then sank by 44.19% to $13.3 million in 2023, then jumped by 100.72% to $26.6 million in 2024, then surged by 38.12% to $36.8 million in 2025.
• The last three Cash & Equivalents figures came in at $36.8 million (Q4 2025), $21.9 million (Q3 2025), and $18.7 million (Q2 2025), per Business Quant data.

Peer Comparison